Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
The aim of this study was to evaluate the HSD17B1 gene polymorphisms in the risks of endometrial cancer, endometriosis and uterine leiomyoma by meta-analysis. A comprehensive electronic search was conducted in PubMed, Medline (Ovid), Embase, Weipu, Wanfang and CNKI. The pooled ORs were performed using the Revman 5.2 softerware. 8 case-control studies were included: 3 were about endometrial cancer, 4 were about endometriosis and 1 was about uterine leiomyoma. The result showed no significant association between HSD17B1 rs605059 gene polymorphisms and risks of endometrial cancer (AA vs. AG+GG: OR = 1.11, 95% CI = 0.94-1.32; AA+AG vs. GG: OR = 1.79, 95% CI = 0.42-7.52; AG vs. AA+ GG: OR = 0.87, 95% CI = 0.76-1.00; AA vs. GG: OR = 1.43, 95% CI = 0.62-3.30; A vs. G: OR = 1.00, 95% CI = 0.91-1.11) or endometriosis (AA vs. AG+GG: OR = 0.99, 95% CI = 0.75-1.32; AA+AG vs. GG: OR = 1.73, 95% CI = 0.92-3.25; AG vs. AA+ GG: OR = 1.24, 95% CI = 1.00-1.53; AA vs. GG: OR = 1.54, 95% CI = 0.79-2.97; A vs. G: OR = 1.23, 95% CI = 0.90-1.68). No association was found in a subgroup analysis based on Asian ethnicity for endometriosis. This meta-analysis suggested that HSD17B1 rs605059 polymorphisms were not associated with the risks of endometrial cancer and endometriosis. Further studies are needed to validate the conclusion and clarify the relationship between HSD17B1 rs605059 polymorphisms and the risk of uterine leiomyoma.
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China ; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy Chengdu 610041, Sichuan, P. R. China.
Xiyan
X
Mu
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Xue
X
Du
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Kui
K
Yao
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Jitong
J
Zhao
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Ce
C
Bian
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Qiao
Q
Wang
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Hongwei
H
Ma
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Tao
T
Yi
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy Chengdu 610041, Sichuan, P. R. China.
Yang
Y
Wu
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University Chengdu 610041, Sichuan, P. R. China.
Xia
X
Zhao
D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D004715:Endometriosis / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D004960:Estradiol Dehydrogenases / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D012307:Risk Factors; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*
D004960:Estradiol Dehydrogenases; C513331:HSD17B1 protein, human
Endometrial cancer; HSD17B1; endometriosis; leiomyoma; meta-analysis; polymorphism